ijms-logo

Journal Browser

Journal Browser

Biomarkers of Tumor Progression, Prognosis and Therapy: 2nd Edition

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Oncology".

Deadline for manuscript submissions: 31 July 2024 | Viewed by 567

Special Issue Editor


E-Mail Website
Guest Editor
Department of Pathology and Experimental Cancer Research, Semmelweis University, H-1085 Budapest, Hungary
Interests: biomarkers of tumor development; progression and prognosis; targeted cancer therapy
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Though cancer development and progression involve the aberrations of complex cellular pathways at the genetic and epigenetic levels, detection of a set of selected biomarkers may have prognostic relevance and/or may offer targets for tumor therapy. These biomarkers can be either directly related to cancer evolution, such as tumor driver/oncogenes and their protein products, or can reflect e.g., protective responses of cancer to hypoxia or the body’s defense mechanisms against carcinogenesis, or reveal impaired cell-death mechanisms. Biomarkers can be discovered at different levels including DNA, the transcribed mRNA, and its epigenetic regulators, miRNAs, as well as the translated proteins which may deregulate essential cell functions and lead to cancer and its aggressive progression. Besides functional testing, advanced molecular methods can be used and combined for identifying cancer biomarkers including next generation sequencing (NGS), in situ hybridization, immunological methods, and proteomics. Research data can be supported by the in silico analysis of biomarker databases and machine-learning- and artificial-intelligence-based automated image analysis of in situ-detected molecules.

This Special Issue “Biomarkers of Tumor Progression, Prognosis and Therapy 2.0” of the International Journal of Molecular Sciences aims to introduce novel biomarkers and review established ones which may have important impacts on tumor fate by using and combining up-to-date in silico, in vitro, and in situ molecular methods in a range of cancer types.

Prof. Dr. Tibor Krenacs
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cancer biomarkers
  • genetic aberrations
  • carcinogenesis
  • cancer progression
  • molecular methods
  • in silico data analysis
  • image analysis
  • proteomics

Related Special Issue

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

21 pages, 12450 KiB  
Article
Comprehensive Analysis of a Six-Gene Signature Predicting Survival and Immune Infiltration of Liposarcoma Patients and Deciphering Its Therapeutic Significance
by Jiayang Han, Binbin Zhao, Xu Han, Tiantian Sun, Man Yue, Mengwen Hou, Jialin Wu, Mengjie Tu and Yang An
Int. J. Mol. Sci. 2024, 25(14), 7792; https://doi.org/10.3390/ijms25147792 (registering DOI) - 16 Jul 2024
Abstract
Background: As a common soft tissue sarcoma, liposarcoma (LPS) is a heterogeneous malignant tumor derived from adipose tissue. Due to the high risk of metastasis and recurrence, the prognosis of LPS remains unfavorable. To improve clinical treatment, a robust risk prediction model is [...] Read more.
Background: As a common soft tissue sarcoma, liposarcoma (LPS) is a heterogeneous malignant tumor derived from adipose tissue. Due to the high risk of metastasis and recurrence, the prognosis of LPS remains unfavorable. To improve clinical treatment, a robust risk prediction model is essential to evaluate the prognosis of LPS patients. Methods: By comprehensive analysis of data derived from GEO datasets, differentially expressed genes (DEGs) were obtained. Univariate and Lasso Cox regressions were subsequently employed to reveal distant recurrence-free survival (DRFS)-associated DEGs and develop a prognostic gene signature, which was assessed by Kaplan–Meier survival and ROC curve. GSEA and immune infiltration analyses were conducted to illuminate molecular mechanisms and immune correlations of this model in LPS progression. Furthermore, a correlation analysis was involved to decipher the therapeutic significance of this model for LPS. Results: A six-gene signature was developed to predict DRFS of LPS patients and showed higher precision performance in more aggressive LPS subtypes. Then, a nomogram was further established for clinical application based on this risk model. Via GSEA, the high-risk group was significantly enriched in cell cycle-related pathways. In the LPS microenvironment, neutrophils, memory B cells and resting mast cells exhibited significant differences in cell abundance between high-risk and low-risk patients. Moreover, this model was significantly correlated with therapeutic targets. Conclusion: A prognostic six-gene signature was developed and significantly associated with cell cycle pathways and therapeutic target genes, which could provide new insights into risk assessment of LPS progression and therapeutic strategies for LPS patients to improve their prognosis. Full article
(This article belongs to the Special Issue Biomarkers of Tumor Progression, Prognosis and Therapy: 2nd Edition)
Show Figures

Figure 1

Back to TopTop